Search
NGD-4715
go.drugbank.com/drugs/DB06027ExperimentalNGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.
Midecamycin
go.drugbank.com/drugs/DB13456InvestigationalIn this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar.
Methazolamide
go.drugbank.com/drugs/DB00703ApprovedA carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
MF101
go.drugbank.com/drugs/DB05052InvestigationalMF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women. … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation
ATN-161
go.drugbank.com/drugs/DB05491InvestigationalIt inhibits the migration and adhesion of particular integrins on activated endothelial cells that play a critical role in tumor angiogenesis. … This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective in single therapy as well as combination therapy.
Elsamitrucin
go.drugbank.com/drugs/DB05129InvestigationalThe cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873)
Phenylmercuric acetate
go.drugbank.com/drugs/DB17044ExperimentalPhenylmercuric acetate is an organomercurial compound used as a fungicide and slimicide.[A253082]
Categories: Compounds used in a research, industrial, or household settingGTS-21
go.drugbank.com/drugs/DB05708Investigationalrelated and memory related tasks (Kitagawa, et al. … GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated.
Sutilain
go.drugbank.com/drugs/DB09379ApprovedWithdrawn[T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368]
Affitope AD01
go.drugbank.com/drugs/DB06086InvestigationalAffitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease. … AD01 is a short peptide (7 amino acids in length) that induces Aß-targeting antibodies, therefore lowering Aß aggregates.